Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH7OIA)

• Drug Name: Infliximab Drug Info
• Synonyms: Remicade (TN)

Indication

Disease Entry	ICD 11	Status	REF
Crohn disease	DD70	Approved	[1]
Lupus nephritis	4A40.0Y	Approved	[2]
Plaque psoriasis	EA90.0	Approved	[3]
Psoriatic arthritis	FA21	Approved	[4]
Toxic epidermal necrolysis		Approved	[5]
Ulcerative colitis	DD71	Approved	[6]
Asthma	CA23	Phase 3	[3]
Rheumatoid arthritis	FA20	Phase 2	[7]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[8]

• Therapeutic Class: Immunosuppressive Agents
• Cross-matching ID:
  TTD Drug ID: DMH7OIA
  VARIDT Drug ID: DR00451

Molecule-Related Drug Atlas

Drug(s) Targeting Tumor necrosis factor (TNF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Thalidomide	DM70BU5	Adult T-cell leukemia/lymphoma		Approved	[11]
Nafamostat	DMU1XOD	Pancreatitis	DC31-DC34	Approved	[12]
Pentoxifylline	DMU3DNC	Alcoholic hepatitis	DB94.1	Approved	[13]
Lenalidomide	DM6Q7U4	Adult T-cell leukemia/lymphoma		Approved	[14]
Enbrel	DM7RNP3	Arthritis	FA20	Approved	[15]
Golimumab	DMHZV7X	Psoriatic arthritis	FA21	Approved	[16]
Certolizumab	DM5CL9Z	Rheumatoid arthritis	FA20	Approved	[17]
Etanercept	DMCV109	Arthritis	FA20	Approved	[18]
Adalimumab	DMQMV1B	Crohn disease	DD70	Approved	[19]
Golnerminogene pradenovac	DMKWV4B	Esophageal cancer	2B70	Phase 3	[20]

Drug(s) Affected By Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[21]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[22]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[23]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[24]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[25]
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[26]
Rituximab	DM1YVZT	Central nervous system non-hodgkin lymphoma		Approved	[27]
Cetuximab	DMLNCE0	Colorectal cancer	2B91.Z	Approved	[28]
(+)-JQ1	DM1CZSJ	Testicular cancer	2C80	Phase 1	[29]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[30]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor necrosis factor (TNF)	TTF8CQI	TNFA_HUMAN	Not Available	[9]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Low affinity immunoglobulin gamma Fc region receptor III-A (FCGR3A)	OTOWXCF3	FCG3A_HUMAN	Drug Response	[10]

References

• [1] Management of inflammatory bowel disease. Med J Aust. 2018 Sep 1;209(7):318-323.
• [2] Infliximab biosimilar-induced lupus nephritis: A case report. Mod Rheumatol Case Rep. 2023 Dec 29;8(1):74-76.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5004).
• [4] Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020 Feb;6(1):e001117.
• [5] Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database Syst Rev. 2022 Mar 11;3(3):CD013130.
• [6] Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462-76.
• [7] ClinicalTrials.gov (NCT00029042) Infliximab to Treat Children With Juvenile Rheumatoid Arthritis
• [8] Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020 May 2;395(10234):1407-1409.
• [9] Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
• [10] Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis. Ann Rheum Dis. 2009 Oct;68(10):1547-52. doi: 10.1136/ard.2008.096982. Epub 2008 Oct 17.
• [11] Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
• [12] Clinical pipeline report, company report or official report of AstraZeneca (2009).
• [13] Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
• [14] Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
• [15] Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
• [16] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [17] Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
• [18] The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
• [19] Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
• [20] TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience... Ann Surg Oncol. 2005 Oct;12(10):825-30.
• [21] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [22] Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
• [23] Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
• [24] Human 3D multicellular microtissues: an upgraded model for the in vitro mechanistic investigation of inflammation-associated drug toxicity. Toxicol Lett. 2019 Sep 15;312:34-44.
• [25] Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod. 2011 Jul;26(7):1813-25.
• [26] Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology. 2007 Dec;12(6):511-7. doi: 10.1080/10245330701562535.
• [27] FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006 Oct 15;108(8):2720-5. doi: 10.1182/blood-2006-01-009480. Epub 2006 Apr 11.
• [28] FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. doi: 10.1200/JCO.2006.08.8021.
• [29] Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells. J Biol Chem. 2012 Dec 14;287(51):43137-55.
• [30] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.